MX2023005203A - Nanoparticulas lipidicas para administrar vacunas de arnm. - Google Patents

Nanoparticulas lipidicas para administrar vacunas de arnm.

Info

Publication number
MX2023005203A
MX2023005203A MX2023005203A MX2023005203A MX2023005203A MX 2023005203 A MX2023005203 A MX 2023005203A MX 2023005203 A MX2023005203 A MX 2023005203A MX 2023005203 A MX2023005203 A MX 2023005203A MX 2023005203 A MX2023005203 A MX 2023005203A
Authority
MX
Mexico
Prior art keywords
lipid nanoparticles
mrna vaccines
delivering mrna
delivering
mrna
Prior art date
Application number
MX2023005203A
Other languages
English (en)
Spanish (es)
Inventor
Frank Derosa
Anusha Dias
Shrirang Karve
Asad Khanmohammed
Khang Anh Tran
Danilo Casimiro
Timothy Tibbitts
Sudha Chivukula
Rebecca L Goldman
Hardip Rajeshbhai Gopani
Kirill Kalnin
Priyal Patel
Timothy Plitnik
Ashish L Sarode
Montoya Natalia Vargas
Angela Lynne Beaulieu
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Priority claimed from PCT/US2021/058250 external-priority patent/WO2022099003A1/en
Publication of MX2023005203A publication Critical patent/MX2023005203A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5123Organic compounds, e.g. fats, sugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2023005203A 2020-11-06 2021-11-05 Nanoparticulas lipidicas para administrar vacunas de arnm. MX2023005203A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063110965P 2020-11-06 2020-11-06
US202163212523P 2021-06-18 2021-06-18
EP21315198 2021-10-13
PCT/US2021/058250 WO2022099003A1 (en) 2020-11-06 2021-11-05 Lipid nanoparticles for delivering mrna vaccines

Publications (1)

Publication Number Publication Date
MX2023005203A true MX2023005203A (es) 2023-07-13

Family

ID=86184333

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005203A MX2023005203A (es) 2020-11-06 2021-11-05 Nanoparticulas lipidicas para administrar vacunas de arnm.

Country Status (9)

Country Link
EP (1) EP4240335A1 (https=)
JP (1) JP7817257B2 (https=)
KR (1) KR20230104223A (https=)
CN (1) CN116406299A (https=)
AU (1) AU2021374976A1 (https=)
CA (1) CA3194325A1 (https=)
CO (1) CO2023005218A2 (https=)
IL (1) IL302631A (https=)
MX (1) MX2023005203A (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017020026A1 (en) 2015-07-30 2017-02-02 Modernatx, Inc. Concatemeric peptide epitopes rnas
TW201729835A (zh) 2015-10-22 2017-09-01 現代公司 呼吸道病毒疫苗
WO2019148101A1 (en) 2018-01-29 2019-08-01 Modernatx, Inc. Rsv rna vaccines
EP4612301A1 (en) * 2022-11-03 2025-09-10 ModernaTX, Inc. Chemical stability of mrna
CN118021957A (zh) * 2022-11-11 2024-05-14 深圳先进技术研究院 一种编码抗禽流感H7N9病毒抗体的mRNA及其制法和应用
CN118021956A (zh) * 2022-11-11 2024-05-14 深圳先进技术研究院 一种编码抗禽流感H7N9病毒抗体的mRNA及其制法和应用
WO2025054383A1 (en) * 2023-09-06 2025-03-13 Modernatx, Inc. Chemical stability of mrna
WO2025092866A1 (zh) * 2023-10-31 2025-05-08 仁景(苏州)生物科技有限公司 一种多价流感mRNA疫苗
CN120053395A (zh) * 2023-11-30 2025-05-30 苏州维益生物科技有限公司 含二硫键的核酸-脂质颗粒、药物、用途、及制备方法
CN118725043B (zh) * 2024-06-27 2025-12-05 中国人民解放军陆军军医大学 用于递送核酸的多肽-脂质组合物及其应用和mRNA疫苗
CN119746089B (zh) * 2025-03-07 2025-06-13 细胞生态海河实验室 脂质纳米颗粒冷冻保护剂
CN121466311A (zh) * 2026-01-09 2026-02-06 羿美诚健(上海)生物医药有限公司 一种脂质组合物及其在核酸递送中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170143848A1 (en) * 2014-03-24 2017-05-25 Shire Human Genetic Therapies, Inc. Mrna therapy for the treatment of ocular diseases
ES2949540T3 (es) * 2015-06-19 2023-09-29 Massachusetts Inst Technology 2,5-piperazinadionas sustituidas con alquenilo y su uso en composiciones para suministrar un agente a un sujeto o una célula
TW202309002A (zh) * 2021-04-15 2023-03-01 美商轉譯生技公司 基於「古德」緩衝液的陽離子脂質

Also Published As

Publication number Publication date
IL302631A (en) 2023-07-01
JP7817257B2 (ja) 2026-02-18
CA3194325A1 (en) 2022-05-12
AU2021374976A1 (en) 2023-06-29
CN116406299A (zh) 2023-07-07
CO2023005218A2 (es) 2023-05-19
KR20230104223A (ko) 2023-07-07
JP2023550600A (ja) 2023-12-04
EP4240335A1 (en) 2023-09-13

Similar Documents

Publication Publication Date Title
MX2023005203A (es) Nanoparticulas lipidicas para administrar vacunas de arnm.
PH12023500013A1 (en) Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
MX2022007680A (es) Nanoparticulas lipidicas para administracion de acidos nucleicos.
MX2024001138A (es) Arn guia modificados.
GB2600859B (en) Improved lipid nanoparticles for delivery of nucleic acids
WO2020051220A8 (en) Compositions and methods for organ specific delivery of nucleic acids
MX2024015149A (es) Lipidos cationicos ionizables y nanoparticulas lipidicas, y metodos de sintesis y uso de los mismos
MX2023005697A (es) Composiciones y metodos para la estabilizacion de vacunas de arnm en nanoparticulas lipidicas.
ZA202103233B (en) Lipid nanoparticle formulations
PH12020552100A1 (en) Modified guide rnas for gene editing
GB202100678D0 (en) Lipid nanoparticle compositions of delivery of mrna and long nucleic acids
WO2022155530A8 (en) Variant strain-based coronavirus vaccines
MX2024002726A (es) Nuevas nanoparticulas lipidicas para la administracion de acidos nucleicos.
MX2024004432A (es) Composiciones dirigidas.
MX2024000327A (es) Composiciones y metodos para la administracion de arn mensajero.
PH12018500965A1 (en) Methods and compositions for gene editing in hematopoietic stem cells
EP4036079A3 (en) Compounds and compositions for intracellular delivery of agents
WO2011038160A3 (en) Compositions and methods for silencing genes expressed in cancer
IL317109A (en) Lipid nanoparticles for the delivery of nucleic acids and methods of using them
AU2013242512A8 (en) RNA formulation for immunotherapy
GB2538683A8 (en) Irinotecan hydrochloride composite phospholipid composition preparation method and use thereof
EP2574170A4 (en) IMMUNOSTIMULATORY AND VACCINE COMPOSITIONS
MX2017011298A (es) Métodos para tratar cáncer que albergan la pérdida hemicigota de tp53.
MX2015000188A (es) Metodo para producir iduronato-2-sulfatasa recombinante.
AU2017260426A1 (en) Engineered nucleases useful for treatment of hemophilia A